Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$614K Buy
1,695
+77
+5% +$26.4K 0.19% 73
2026
Q1
$569K Buy
1,618
+7
+0.4% +$2.5K 0.2% 69
2025
Q4
$527K Buy
1,611
+12
+0.8% +$3.81K 0.2% 70
2025
Q3
$451K Buy
1,599
+251
+19% +$72.8K 0.18% 73
2025
Q2
$376K Buy
1,348
+8
+0.6% +$2.27K 0.17% 80
2025
Q1
$417K Buy
1,340
+139
+12% +$41K 0.2% 71
2024
Q4
$313K Sell
1,201
-3
-0.2% -$890 0.16% 79
2024
Q3
$388K Buy
1,204
+51
+4% +$16.7K 0.19% 71
2024
Q2
$360K Buy
1,153
+105
+10% +$30.8K 0.2% 70
2024
Q1
$298K Buy
1,048
+182
+21% +$53.3K 0.17% 84
2023
Q4
$249K Buy
866
+5
+0.6% +$1.36K 0.15% 85
2023
Q3
$231K Buy
+861
New +$215K 0.16% 83
2023
Q2
Sell
-851
Closed -$206K 91
2023
Q1
$206K Buy
851
+5
+0.6% +$1.23K 0.14% 91
2022
Q4
$222K Buy
+846
New +$227K 0.16% 87

Other funds holding AMGN

Powers Advisory Group's AMGN Position: Q2 2026 in Review

Powers Advisory Group increased its Amgen (AMGN) stake by 4.8% in Q2 2026, buying an estimated $26.4K and bringing the position to 1,695 shares worth $614K. The position accounts for 0.19% of the portfolio, ranked #73.

Powers Advisory Group first reported a position in AMGN in Q4 2022 and has held it in 14 quarters since. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Powers Advisory Group held 1,695 shares of Amgen worth $614K as of Q2 2026.
  • Powers Advisory Group bought 77 Amgen shares in Q2 2026, an estimated $26.4K.
  • Amgen made up 0.19% of Powers Advisory Group's portfolio in Q2 2026, its #73 holding.
  • Powers Advisory Group first reported a position in Amgen in Q4 2022 and has held it in 14 quarters since.
  • 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Powers Advisory Group's 13F filing for Q2 2026, filed 31 Jul 2026.